Top Industry Leaders in the Oral Mucositis Market
OncoMed Announced positive Phase 2b data for navicixumab (OM1901), its investigational monoclonal antibody for the prevention of radiation-induced OM in head and neck cancer patients.
Soligenix Launched NeuMucof-G, a topical oral rinse for the management of OM in head and neck cancer patients. This marks the company's first commercialization of an OM product.
OraPharma Received FDA Fast Track designation for OP01501, its topical mucosal protectant for the prevention of OM in patients undergoing hematopoietic stem cell transplantation.
EUSA Pharma Successfully completed the Phase 2 clinical trial of palifermin oral rinse for the prevention of OM in patients undergoing stem cell transplantation. Further development plans are underway.
Innovation Pharmaceuticals Partnered with Aizano Medical Technology to develop and commercialize the Aizano Oral Mucositis Relief System, a non-drug device for OM management.
List of Oral Mucositis Key Companies in the Market
-
Izun Pharmaceuticals Corporation
-
Shoreline Pharmaceuticals Inc
-
AMAG Pharmaceutical Inc
-
Innovation Pharmaceuticals
-
Himalaya Drug Company